GEHC

GE HealthCare Technologies Inc.
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$29.42B
P/E Ratio
15.55
EPS
$4.16
Beta
0.84
52W High
$89.69
52W Low
$58.75
50-Day MA
$63.43
200-Day MA
$73.94
Dividend Yield
0.22%
Profit Margin
9.10%
Forward P/E
13.40
PEG Ratio
1.85

About GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$20.98B
Gross Profit (TTM)$8.21B
EBITDA$3.52B
Operating Margin11.10%
Return on Equity19.50%
Return on Assets5.17%
Revenue/Share (TTM)$46.03
Book Value$23.45
Price-to-Book2.80
Price-to-Sales (TTM)1.40
EV/Revenue1.818
EV/EBITDA10.59
Quarterly Earnings Growth (YoY)-30.90%
Quarterly Revenue Growth (YoY)7.40%
Shares Outstanding$454.89M
Float$453.44M
% Insiders0.35%
% Institutions93.86%

Historical Volatility

HV 10-Day
18.82%
HV 20-Day
31.82%
HV 30-Day
28.15%
HV 60-Day
40.51%
HV Rank
28.6%

Volatility is currently contracting

Analyst Ratings

Consensus ($79.22 target)
4
Strong Buy
9
Buy
5
Hold

Latest News

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, July 8, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.   IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC.

PRNewsWire7/8/2026Neutral
GE HealthCare and Mayo Clinic aim to advance personalized cancer treatment through new theranostics research collaboration

CHICAGO & ROCHESTER, Minn.--(BUSINESS WIRE)--GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of.

Business Wire7/8/2026Neutral
GE HealthCare to announce second quarter 2026 results on July 29, 2026

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will.

Business Wire7/8/2026Neutral
GE HealthCare announces cash dividend for second quarter of 2026

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026.About GE HealthCare Technologies Inc.GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle.

Business Wire6/30/2026Neutral
GE HealthCare introduces Allia upgrade pathways designed to modernize existing interventional suites

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced Allia™ platform upgrade pathways designed to help customers modernize select legacy Innova™ and Discovery™ Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations. As procedura.

Business Wire6/29/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026